

NUMBER OF CASES PER YEAR (2010-2014)	NUMBER OF DEATHS PER YEAR (2010-2014)
Male	Male
1,049	251
FIVE-YEAR SURVIVAL (2004-2008)	22-YEAR PREVALENCE (2014)
Male	Male
87.6%	8,785

INCIDENCE

In 2010-2014 there were 1,049 men diagnosed with prostate cancer each year. The risk for men of developing a prostate cancer up to the age of 75 was 1 in 12.


Incidence trends

Table 1: Incidence of prostate cancer and year of diagnosis: 2005-2014

	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014
Male	843	885	972	1,024	1,117	964	1,061	1,072	1,030	1,119

Over a ten year period from 2005 to 2014 the number of prostate cancers cases in men has increased from 843 to 1,119. Prostate cancer incidence rates in men have increased during 1998-2008 by an average of +4.5% per year, and then have decreased by -2.3% from 2008-2014. Incidence rates of prostate cancer have increased internationally. This is primarily a result of the widespread use of prostate specific antigen (PSA) testing which is a blood test that is used as a diagnostic approach to detect prostate cancer at an early stage but which also detects very slowly growing cancers that would never cause any problems or symptoms in a man's lifetime.

Figure 1: Trends in prostate cancer incidence rates: 1993-2014



Incidence and age


Prostate cancer risk is strongly related to age with approximately 70% of patients diagnosed over the age of 65 years and incidence rates greatest among those aged over 70.

Table 2: Average number of prostate cancers diagnosed per year by age: 2010-2014

Age	Male
0 to 49	18
50 to 64	290
65 to 74	393
75 and over	348
All ages	1,049

Due to rounding of yearly averages, 'All ages' may not equal the sum of age categories in tables.


Figure 2: Incidence of prostate cancer by age: 2010-2014



Incidence by Trust area

Prostate cancer incidence rates in 2010-2014 were 9% higher among people living in the Northern Trust area than in Northern Ireland as a whole while those living in Belfast and the South-Eastern Trust areas had 7% lower incidence of prostate cancer than the Northern Ireland Average.

Figure 3: Prostate cancer incidence rates compared to the NI average by sex and HSC Trust of residence: 2010-2014



© Crown Copyright and database rights NIMA MOU207.2


Significantly higher than average

Significantly lower than average

Incidence by deprivation

Prostate cancer incidence rates varied depending upon socio-economic deprivation. Incidence is significantly lower (-8%) in the most-deprived areas in comparison to Northern Ireland as a whole. This pattern most likely reflects higher rates of PSA testing in the most-affluent communities compared to the most-deprived.

Figure 4: Prostate cancer incidence rates compared to the NI average by deprivation quintile: 2010-2014




Incidence by stage

Cancer stage is a way of describing the size of a cancer and how far it has grown and spread. This information is important in helping decide what treatments are needed and stage of disease at diagnosis is strongly associated with cancer survival.

From 2010 to 2014 88% of prostate cancer patients in Northern Ireland were assigned a stage at diagnosis.

The majority of prostate cancer patients were diagnosed at early stage (20.9% at stage I and 34.3% at Stage II) and 15.1% diagnosed at late stage (stage IV).

Figure 5: Prostate cancer stage distribution: 2010-2014



SURVIVAL

The net survival was 97.7% at one year, and 87.6% at five years for prostate cancer patients diagnosed in 2005 to 2009.

Table 3: Five-year prostate cancer survival by survival time: patients diagnosed 2005-2009

Time since diagnosis	Diagnosed 2005-2009
	Male
6 months	97.7%
1 year	96.4%
5 years	87.6%

Survival Trends

Five-year survival for prostate cancer in men has improved from 60.4% in the 1994-1999 diagnosis period to 87.6% in the 2005-2009 diagnosis period. Improvements are largely due to increased detection of slow growing prostate cancer and increasing diagnosis in younger men because of PSA testing. Consequently, epidemiologists consider mortality rates as a better indicator of cancer outcome than survival


Table 4: Five-year prostate cancer survival by period of diagnosis

Period of diagnosis	Male
1994-1999	60.4%
2000-2004	81.3%
2005-2009	87.6%

Survival and stage

Stage at diagnosis is one of the most important factors in prostate cancer survival with one-year survival decreasing as stage increases. Stage at diagnosis data is available for cancer patients diagnosed since 2009. One-year survival was 100% for all patients except those diagnosed with late stage IV disease (82.8%).

Figure 6: One year survival from prostate cancer by stage of diagnosis: patients diagnosed 2009-2013



MORTALITY


Mortality statistics are provided by the Northern Ireland General Registrar's Office. In 2010-2014 there were 251 deaths from prostate cancer each year.

Mortality trends

Over the last ten years the number of prostate cancer deaths has not changed significantly from 221 among men in 2005 to 239 among men in 2014.

When adjusted for age and population change, prostate cancer mortality rates decreased by -1.1% per year during 1993-2014.

Figure 7: Trends in prostate cancer mortality rates: 1993-2014



PREVALENCE

At the end of 2014 there were 8,785 men living in NI who had been diagnosed with prostate cancer from 1993-2014 (Table 5). Of these, 65.3% were aged 70 and over and 12.2% had been diagnosed in the previous year.

Table 5: Number of men living with prostate cancer at the end of 2014 who were diagnosed from 1993-2014 by time since diagnosis

Sex	Age	Time since diagnosis				22-year Prevalence
		0-1 year	1-5 years	5-10 years	10-22 years	
Male	0-69	536	1439	884	191	3,050
	70+	539	1,852	2,088	1,256	5,735
	All ages	1,075	3,291	2,972	1,447	8,786

FURTHER INFORMATION

Further data is available from the Northern Ireland Cancer Registry web site: www.qub.ac.uk/nicr

NI Cancer Registry
Phone: +44 (0)28 9063 2573
e-mail: nicr@qub.ac.uk



ACKNOWLEDGEMENTS

NICR is funded by the Public Health Agency and is hosted by Queen's University, Belfast.

